HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France’s Mayoly Spindler Set To Acquire Ipsen’s Consumer Business

Executive Summary

Mayoly Spindler is stepping up its presence in the self-care market with the acquisition of Ipsen's Consumer Healthcare business, which has been under strategic review for the past year.

You may also be interested in...



People On The Move: Appointments At Haleon, Mayoly Spindler And Lonza

Round-up of European consumer health industry appointments: Haleon hires M&A and BD head from Associated British Foods; Mayoly Spindler promotes Giraud to CEO; and Lonza names president of capsules and health ingredients.

EU Business News: Orkla Acquires Healthspan, Bayer Invests Locally, Ipsen Targets Baltics

A round-up of the latest European consumer health business news: Norway's Orkla strengthens its supplements offering with acquisition of UK's Healthspan; Bayer makes investment commitment to German Consumer Health operation; and Ipsen strikes a deal to promote brands in the Baltics.

EU Business News: GSK Consumer Gets New Name, Navamedic Strikes Ipsen Deal, Enzymatica Optimistic After Tough Year

Round-up of the latest European consumer health business news: GSK reveals name for standalone consumer health business will be Haleon; Norways' Navamedic strikes a distribution deal with Ipsen for select GI OTC products; and Sweden's Enzymatica hopeful that changed consumer behaviors will help its sales rebound in 2022.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel